Everything below concerns reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-03. Numbers and descriptions here follow the published literature rather than marketing material.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
=== Sri Lanka === The primary operational ration of the Sri Lanka Armed Forces is the Jungle Ration, a 24-hour ration pack whose components are produced and assembled in Sri Lanka. It is issued to soldiers at the rate of one per soldier per day, and contains both food and sun-dry items designed to sustain troops where food storage and preparation facilities are not practical. All meals are precooked, requiring neither cooking nor preparation, and all items are packaged inside sealed plastic packages or lightweight aluminium cans. Precooked rice is included as part of every meal. Typical contents are: chicken curry with potatoes, vegetable curry, precooked rice, hard crackers, processed cheese, soup cubes, instant milk powder, orange drink powder, and dates or dried pineapple. A sundry pack containing tea bags, sugar, salt, glucose tablets, seasonings, matches, plastic bags, and toilet paper is included with every ration pack.
== Sources == Meredith, Martin (2010). Mandela: A Biography. New York: PublicAffairs. ISBN 978-1-58648-832-1. Sampson, Anthony (2011) [1999]. Mandela: The Authorised Biography. London: HarperCollins. ISBN 978-0-00-743797-9.
sex linkage The presence of a particular gene or DNA sequence on a sex chromosome (in mammals either the X chromosome or the Y chromosome) rather than on an autosome; these genes are said to be sex-linked. Expression of sex-linked genes varies by organism depending on the mechanism of sex determination and the types of sex chromosomes present, but the associated phenotypes often exclusively appear in either the homogametic or heterogametic sex.
Sources: en.wikipedia.org
== Background == As the second largest class of enzymes behind ubiquitin ligases and responsible for ~2% of any organism's genes, proteases have drawn the attention of biologists to develop a field aimed at identifying and quantifying their roles in biology. First coined in 2000 by the Overall Lab in McQuibban et al., degradomics was described as linking proteases to substrates on a proteome basis. The discoveries of novel roles for proteases and breakthroughs in protease-substrate discovery would be summarized later by Dr. Carlos Lopez-Otin and Dr. Chris Overall, introducing degradomics on a system-wide scale. They collated the current and emerging techniques available to describe proteolysis. By drawing attention to how proteolysis serves as an additional irreversible mechanism by which cells could achieve control over biological processes, they outlined the necessity of studying proteases for their functional relevance in processing bioactive molecules. These bioactive molecules play roles in coagulation, complement activation, DNA replication, cell-cycle control, cellular proliferation and migration, hemostasis, immunity, and apoptosis. The degradome was broken down into two concepts, the first referring the entire profile of proteases expressed under by a cell, tissue, or organism under defined circumstances. The second definition applies specifically to the full substrate repertoire of a certain protease in a cell, tissue, or organism. Dr. Overall's group would go on to annotate the complete human and mouse protease-inhibitor degradomes in 2003.
Mostly in the 1990s, several books were published that were critical of cold fusion research methods and the conduct of cold fusion researchers. Over the years, several books have appeared that defended them. Around 1998, the University of Utah had already dropped its research after spending over $1 million, and in the summer of 1997, Japan cut off research and closed its own lab after spending $20 million.
Positively charged ions were found to accumulate in the membrane. Multi-parametric surface plasmon resonance is one of the methods to study barrier properties of natural, modified or coated nanocellulose. The different antifouling, moisture, solvent, antimicrobial barrier formulation quality can be measured on the nanoscale. The adsorption kinetics as well as the degree of swelling can be measured in real-time and label-free.
Sources: en.wikipedia.org
DNA expression requires the transfection of suitable host cells. Typically, either bacterial, yeast, insect, or mammalian cells (such as human embryonic kidney cells or Chinese hamster ovary cells) are used as host cells. Following transplantation into the host organism, the foreign DNA contained within the recombinant DNA construct may or may not be expressed. That is, the DNA may simply be replicated without expression, or it may be transcribed and translated and a recombinant protein is produced. Generally speaking, expression of a foreign gene requires restructuring the gene to include sequences that are required for producing an mRNA molecule that can be used by the host's translational apparatus (e.g. promoter, translational initiation signal, and transcriptional terminator). Specific changes to the host organism may be made to improve expression of the ectopic gene. In addition, changes may be needed to the coding sequences as well, to optimize translation, make the protein soluble, direct the recombinant protein to the proper cellular or extracellular location, and stabilize the protein from degradation.
=== Economic situation === Because of their wide needs, the overall chelating agents growth was 4% annually during 2009–2014 and the trend is likely to increase. Aminopolycarboxylic acids chelators are the most widely consumed chelating agents; however, the percentage of the greener alternative chelators in this category continues to grow. The consumption of traditional aminopolycarboxylates chelators, in particular the EDTA (ethylenediaminetetraacetic acid) and NTA (nitrilotriacetic acid), is declining (−6% annually), because of the persisting concerns over their toxicity and negative environmental impact. In 2013, these greener alternative chelants represented approximately 15% of the total aminopolycarboxylic acids demand. This is expected to rise to around 21% by 2018, replacing and aminophosphonic acids used in cleaning applications. Examples of some Greener alternative chelating agents include ethylenediamine disuccinic acid (EDDS), polyaspartic acid (PASA), methylglycinediacetic acid (MGDA), glutamic diacetic acid (L-GLDA), citrate, gluconic acid, amino acids, plant extracts etc.
== History == Cold hemagglutination was first reported by Landsteiner in 1903 and found to occur in human beings in 1918. The association of cold hemagglutination with hemolysis was described in 1937 by Rosenthal and Corten. During the 1960s, Dacie and Schubothe published systematic descriptions of 16 CAD patients each. The auto antibodies responsible for hemagglutination at low temperatures, cold agglutinins (CA), may be found in the sera of healthy subjects as well as in patients with AIHA of the cold reactive types. CA bind to erythrocyte surface antigens at a temperature optimum of 0–4 °C. In contrast to polyclonal CA in healthy individuals, monoclonal CA often have a high-thermal amplitude, which contributes to their pathogenicity at temperatures approaching 37 °C. Binding of CA causes agglutination of erythrocytes and the antigen–antibody complex induces complement (C) activation and hemolysis. Essential clinical manifestations of primary CAD are hemolytic anemia and cold-induced circulatory symptoms. Exact estimates of the severity of anemia and the frequency of cold-induced symptoms, however, have not been provided until recent years.
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.